CJC-1295 Dosage in Published Studies

I. · Doses used in published human trials

Doses used in published human trials

The published CJC-1295 dosage record in humans rests on two trials reported by Teichman and colleagues in 2006 and one registered Phase 2 trial in HIV-associated visceral obesity [01][18].

In Teichman 2006, healthy adults aged 21 to 61 received single subcutaneous ascending doses of CJC-1295 (DAC variant) at 30, 60, 125, and 250 mcg/kg [01]. A separate multiple-dose arm of the same paper administered weekly or biweekly subcutaneous doses at 30-60 mcg/kg over 28- to 49-day trial windows [01]. The compound was reported well tolerated at 30-60 mcg/kg; injection-site reactions, transient flushing, and headache were the most frequently logged adverse events [01].

The Phase 2 trial in HIV-associated visceral obesity (NCT00267527, sponsor ConjuChem) used weekly escalating subcutaneous doses across two arms: a low arm at 60, 90, and 120 mcg/kg, and a high arm at 60, 120, and 240 mcg/kg, with twelve-week treatment windows in approximately 192 participants [18]. The trial was terminated before completion (see developmental history).

II. · Dosing frequency in published protocols

Dosing frequency in published protocols

The DAC and non-DAC variants belong to two different dosing paradigms because their pharmacokinetics differ by two orders of magnitude.

The DAC variant was administered as weekly subcutaneous injection in human Phase 1 and Phase 2 trials, justified by the multi-day plasma half-life produced by covalent serum-albumin binding [01][12]. A single weekly injection at 30-60 mcg/kg maintained mean IGF-1 above baseline across 28-day trial windows.

The non-DAC variant — modified GRF 1-29 — was administered as multiple daily subcutaneous injections, typically 1-3 times per day, in research protocols owing to its 30-minute plasma half-life [13]. The GH pulse from each non-DAC injection lasts roughly 60-90 minutes [13]. The two variants are not interchangeable on a per-injection basis: the non-DAC variant requires frequent dosing to maintain receptor engagement; the DAC variant requires the opposite restraint.

III. · CJC-1295 Half-Life and Dosing Interval

CJC-1295 Half-Life and Dosing Interval

CJC-1295 half-life splits cleanly along the DAC / non-DAC axis. In Teichman 2006 the estimated plasma half-life of the DAC variant in healthy adults was 5.8 to 8.1 days [01]. The non-DAC variant — modified GRF 1-29 — has a plasma half-life of approximately 30 minutes, extended from the sub-10-minute half-life of native sermorelin by the four DPP-IV-resistant amino-acid substitutions but no further [04][13].

The difference is mechanistic. The DAC linker covalently couples the peptide to Cys34 of serum albumin via maleimide chemistry; albumin's circulating half-life is near 19 days, and the bound peptide rides that turnover [12]. In ConjuChem's preclinical rat assay, immunoreactive albumin-bound CJC-1295 appeared in circulation within 15 minutes of injection and remained detectable beyond 72 hours [03][14]. The 30-minute non-DAC half-life is what DPP-IV resistance alone buys without an albumin carrier.

IV. · Plasma persistence

Plasma persistence

Plasma persistence is a longer window than functional half-life. The DAC variant remains detectable for roughly 14-21 days due to ongoing albumin binding, and effective GHRHR signaling persists for six to eight days per dose [01][12]. The non-DAC variant clears within hours. Antibody-free nano-LC-HRMS/MS methods reach sub-picogram-per-milliliter sensitivity for the peptide in urine [19], and immunoaffinity-capture LC-MS/MS confirmation methods exist for the albumin-bound DAC variant in plasma [09]; both are the analytical foundations of current WADA enforcement.

V. · Routes studied

Routes studied

The subcutaneous route dominates the published clinical record. Teichman 2006 used subcutaneous administration for both single-dose and multiple-dose arms [01], as did the Phase 2 lipodystrophy program [18]. Preclinical rat pharmacokinetics used intravenous and subcutaneous administration [03]; rodent screening assays used intraperitoneal as well [03]. No oral, intramuscular, or intranasal CJC-1295 protocols appear in the published human record.

VI. · Stability and reconstitution context

Stability and reconstitution context

Published technical documentation describes the lyophilized peptide as stable at -20 C [13]. Once reconstituted in bacteriostatic water, the peptide is reported stable refrigerated for several weeks; the DAC variant's maleimide-thiol chemistry is sensitive to oxidation, so the intact peptide is required for in vivo albumin conjugation [13]. This site does not provide reconstitution instructions: that is research-protocol territory, not editorial commentary.

VII. · An editorial caveat on the dose record

An editorial caveat on the dose record

The dose figures above are study-administered values in study-defined populations under study-defined monitoring. They are not dosing recommendations. CJC-1295 has not received FDA approval for any indication, and the U.S. Pharmacy Compounding Advisory Committee declined to add it to the 503A Bulks List in December 2024 [20]. The compound is sold widely as a research chemical from suppliers operating outside pharmaceutical-grade quality control. The published peer-reviewed dosing record covers a small number of trials in a small number of populations and does not constitute a clinical dosing standard.